- Grifols sCD38 is the industry's first-ever soluble
recombinant protein designed to overcome the interference that the
cancer therapy daratumumab has on critical blood-transfusion
tests
- The solution prevents daratumumab, which targets the
CD38 protein on cancer cells, from binding to this specific protein
on red blood cells and interfering in pre-transfusion compatibility
testing
- Grifols sCD38 has received the CE mark and is another
example of the company's commitment to ensure the safety of the
world's blood supply
BARCELONA, Spain, Nov. 16,
2023 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P
NASDAQ: GRFS), one of the world's leading producers of
plasma-derived medicines and innovative diagnostic solutions, today
announced the launch of its new Grifols sCD38 solution, the
industry's first-ever soluble recombinant protein designed to block
anti-CD38 antibodies in multiple myeloma patients receiving
daratumumab therapy, ensuring quick and accurate blood transfusion
tests that are critical for proper treatment.
Daratumumab is a CD38-directed monoclonal antibody for treating
multiple myeloma. However, during treatment the drug binds to the
CD38 protein on red blood cells and can alter the results of
critical blood pre-transfusion tests. This can delay lifesaving
transfusions for these patients.
Grifols sCD38's novel approach enables a more seamless
screening, identification and crossmatching process when using
Grifols' DG Gel system for running pre-transfusion compatibility
tests. When using this solution, laboratories have clearer clinical
pictures with less effort compared with current alternative
solutions.
"We are excited to announce the launch of Grifols sCD38, a
first-of-its-kind solution that simplifies the process of blood
transfusion testing with an easy, seamless methodology," said
Antonio Martínez, president of Grifols Diagnostic Business Unit.
"Certification of Grifols sCD38 provides a reliable and efficient
solution to ensure accurate and consistent results, demonstrating
Grifols' continued commitment to innovating blood transfusion
safety."
The Grifols sCD38 solution has received the CE mark and will be
available in certain markets after completion of any additional
registration and notification requirements.
About DG Gel System
The DG Gel system instruments and reagents use the DG Gel card
technology to help labs streamline pretransfusion compatibility
tests and tailor the extended phenotype profile for each patient's
need. DG Gel system reagents include comprehensive DG Gel card
profiles, reagent red blood cell options and complete liquid
antisera.
To learn more, visit:
https://www.diagnostic.grifols.com/en/dg-gel-system
About Grifols
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the
health and well-being of people around the world. A leader in
essential plasma-derived medicines and transfusion medicine, the
company develops, produces and provides innovative healthcare
services and solutions in more than 110 countries.
Patient needs and Grifols' ever-growing knowledge of many
chronic, rare and prevalent conditions, at times life-threatening,
drive the company's innovation in both plasma and other
biopharmaceuticals to enhance quality of life. Grifols is focused
on treating conditions across a broad range of therapeutic areas:
immunology, hepatology and intensive care, pulmonology, hematology,
neurology and infectious diseases.
A pioneer in the plasma industry, Grifols continues to grow its
network of donation centers, the world's largest with over 390
across North America, Europe, Africa and the Middle East and China.
As a recognized leader in transfusion medicine, Grifols offers a
comprehensive portfolio of solutions designed to enhance safety
from donation to transfusion, in addition to clinical diagnostic
technologies. It provides high-quality biological supplies for
life-science research, clinical trials, and for manufacturing
pharmaceutical and diagnostic products. The company also supplies
tools, information and services that enable hospitals, pharmacies
and healthcare professionals to efficiently deliver expert medical
care.
Grifols, with more than 24,000 employees in more than 30
countries and regions, is committed to a sustainable business model
that sets the standard for continuous innovation, quality, safety
and ethical leadership.
In 2022, Grifols' economic impact in its core countries of
operation was EUR 9.6 billion. The
company also generated 193,000 jobs, including indirect and
induced.
The company's class A shares are listed on the Spanish Stock
Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols
non-voting class B shares are listed on the Mercado Continuo
(MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).
For more information, please visit www.grifols.com
LEGAL DISCLAIMER
The facts and figures contained in this report that do not refer
to historical data are "future projections and assumptions". Words
and expressions such as "believe", "hope", "anticipate", "predict",
"expect", "intend", "should", "will seek to achieve", "it is
estimated", "future" and similar expressions, insofar as they
relate to the Grifols group, are used to identify future
projections and assumptions. These expressions reflect the
assumptions, hypotheses, expectations and predictions of the
management team at the time of writing this report, and these are
subject to a number of factors that mean that the actual results
may be materially different. The future results of the Grifols
group could be affected by events relating to its own activities,
such as a shortage of supplies of raw materials for the manufacture
of its products, the appearance of competitor products on the
market, or changes to the regulatory framework of the markets in
which it operates, among others. At the date of compiling this
report, the Grifols group has adopted the necessary measures to
mitigate the potential impact of these events. Grifols, S.A. does
not accept any obligation to publicly report, revise or update
future projections or assumptions to adapt them to events or
circumstances subsequent to the date of writing this report, except
where expressly required by the applicable legislation. This
document does not constitute an offer or invitation to buy or
subscribe shares in accordance with the provisions of the following
Spanish legislation: Royal Legislative Decree 4/2015, of 23
October, approving recast text of Securities Market Law;
Royal Decree Law 5/2005, of 11 March
and/or Royal Decree 1310/2005, of 4
November, and any regulations developing this legislation. In
addition, this document does not constitute an offer of purchase,
sale or exchange, or a request for an offer of purchase, sale or
exchange of securities, or a request for any vote or approval in
any other jurisdiction. The information included in this document
has not been verified nor reviewed by the external auditors of the
Grifols group
Logo -
https://mma.prnewswire.com/media/847347/Grifols_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/grifols-launches-new-solution-to-facilitate-pre-transfusion-compatibility-testing-in-multiple-myeloma-patients-301989753.html
